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Abstract
In addition to the mutations that underlie most cases of the multiple
endocrine neoplasia type 1 (MEN1) syndrome, somatic mutations of
the MEN1 gene have also been described in sporadic tumors like
gastrinomas, insulinomas and bronchial carcinoid neoplasm. We ex-
amined exon 2 of this gene, where most of the mutations have been
described, in 148 endocrine and nonendocrine sporadic tumors. DNA
was obtained by phenol/chloroform extraction and ethanol precipita-
tion from 92 formalin-fixed, paraffin-embedded samples, and from 40
fresh tumor tissue samples. We used 5 pairs of primers to encompass
the complete coding sequence of exon 2 of the MEN1 gene that was
screened by the polymerase chain reaction-single-stranded conforma-
tion polymorphism (PCR-SSCP) technique in 78 sporadic thyroid
cancers: 28 follicular adenomas, 35 papillary carcinomas, 14 follicu-
lar carcinomas, and 1 anaplastic thyroid carcinoma. We also examined
46 adrenal lesions (3 hyperplasias, 3 adenomas and 35 adrenocortical
carcinomas, 2 pheochromocytomas, 2 ganglioneuroblastomas, and 1
lymphoma) and 24 breast cancers (6 noninvasive, 16 infiltrating
ductal, and 2 invasive lobular tumors). The PCR product of 5 tumors
suspected to present band shifts by SSCP was cloned. Direct sense and
antisense sequencing did not identify mutations. These results suggest
that the MEN1 gene is not important in breast, thyroid or adrenal
sporadic tumorigenesis. Because the frequency of mutations varies
significantly among tumor subgroups and allelic deletions are fre-
quently observed at 11q13 in thyroid and adrenal cancers, another
tumor suppressor gene residing in this region is likely to be involved
in the tumorigenesis of these neoplasms.
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Multiple endocrine neoplasia type 1
(MEN1) is characterized by the development
of endocrine tumors of the parathyroid and
pituitary glands, pancreas, and duodenum.
Less frequently, other nonendocrine tumors
such as lipomas and angiofibromas are asso-
ciated with MEN1 (1,2). An increased inci-
dence of thyroid neoplasms, leiomyomas,
adrenocortical tumors, hepatic focal nodular
hyperplasia, and renal angiomyolipoma has
also been described in MEN1 families (1,2).
There are reports of MEN1 patients with
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complex series of tumors like esophageal
leiomyomas, hepatic neuroendocrine metas-
tasis, etc. (1,2). The MEN1 gene has recently
been identified and found to be widely ex-
pressed (3). Although the function of the
nuclear protein encoded by the gene, called
menin, remains unclear, it is recognized that
the gene acts as a tumor suppressor gene
since many of the identified menin germline
mutations and mutations in sporadic tumors
would lead to inactivation of menin or to C-
terminally truncated proteins which would
result in loss of repression of MEN1/JunD
target genes (4).
Familial syndromes are a good starting
point to look for tumor suppressor genes.
The nonhereditary forms of the tumors pres-
ent in these familial syndromes frequently
present the same tumor suppressor gene in-
activation, usually associated with some more
gene mutations. Hence, a wide series of spo-
radic tumors has already been explored for
MEN1 mutations. Inactivating mutations have
been described in sporadic parathyroid ad-
enomas (21%), gastrinomas (33%), bron-
chial carcinoid tumors (36%), and occasion-
ally, pituitary tumors (5-8). Because of the
vast phenotype presentation of MEN1 syn-
drome, we decided to look for mutations of
this gene in a wide series of sporadic tumors
that are not directly related to the syndrome.
The institutional Committee on Ethics in
Medical Research approved the study of a
total of 148 patients (82 women and 66 men)
who gave informed consent to participate.
There were 121 endocrine tumors consisting
of 78 sporadic thyroid cancers: 28 follicular
adenomas, 35 papillary carcinomas, 14 folli-
cular carcinomas, and 1 anaplastic thyroid
carcinoma, and of 43 adrenal lesions: 3 hy-
perplasias, 3 adenomas, 35 adrenocortical
carcinomas, and 2 pheochromocytomas. We
also studied 27 patients with nonendocrine
tumors consisting of 24 breast cancers (6
noninvasive, 16 infiltrating ductal, and 2
invasive lobular tumors) and of 2 ganglio-
neuroblastomas and 1 solid lymphoma of the
adrenal gland. Patient age ranged from 4 to
78 years. Seventeen cases of adrenal tumors
and 2 thyroid tumors were from children (4
to 16 years old). Forty samples were ob-
tained at surgery, snap frozen and kept at
-80oC until processed. The other specimens
were embedded in paraffin and selected from
pathology archives. We were able to obtain
normal tissue from the nonaffected lobe of
12 thyroid tumors. Tissue slices of lesions
excised from the affected patients were re-
viewed by two of the authors (P.S.M. and
L.H.C-L.) for confirmation of the diagnosis.
Also, a section of each paraffin block was
stained with hematoxylin-eosin and reviewed
for diagnosis confirmation by the same pa-
thologists. Tumoral tissue was carefully mi-
crodissected from the paraffin or the frozen
blocks. The frozen tissues were ground un-
der liquid nitrogen and DNA was extracted
with the Trizol reagent (Life Technologies,
Grand Island, NY, USA) according to manu-
facturer instructions. Five to 10 sections of
15 µm were cut from each of the paraffin-
embedded tissue blocks and submitted to
overnight digestion with proteinase K. After
phenol/chloroform extraction, the samples
were precipitated in ethanol and then resus-
pended. The DNA concentration was deter-
mined by absorbance measurements at 260/
280 nm. All samples were stored at -20oC
until they were used.
We designed primers to encompass all
exon 2 sequence because most of the muta-
tions so far described in unrelated MEN1
patients with the same mutation concern
this exon. The primers utilized are listed in
Table 1.
Single-stranded conformational polymor-
phism (SSCP) analysis was performed by
the Phast System-Pharmacia method (Phar-
macia, Uppsala, Sweden) according to manu-
facturer instructions. Briefly, PCR was per-
formed with 200 ng genomic DNA, 10 pmol
of each primer, 100 µM dNTPs, different
MgCl2 concentrations for each pair of prim-
ers, 10 mM Tris-HCl, pH 9.0, at 25oC, 50
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mM KCl, and 1 U Taq polymerase in a final
volume of 20 µl. Thirty-five cycles of dena-
turation (94oC), annealing (52o to 62oC) and
extension (72oC) were conducted on an au-
tomated heat block (DNA thermal cycler,
Perkin Elmer/Cetus, Norwalk, CT, USA).
The reaction mixture was then diluted in
DNA gel loading buffer, denatured and
loaded onto the gel. Gels were stained with
AgNO3 and photographed. All cases were
screened at least twice by SSCP for the
presence of an aberrant band in tumor DNA
compared to normal DNA. Five PCR-ampli-
fied products presented shifts of bands on
the SSCP gel and their DNA was reamplified
by PCR. The PCR products were then cloned
into a pGEM vector (Promega Corp., Madi-
son, WI, USA). Finally, strand and antistrand
DNA was run on the automated sequencer
ABI 3776 (Perkin Elmer).
Figure 1 shows a representative example
of PCR-SSCP analysis. We were unable to
find any mutation among the screened cases.
All five cases suspected to present band
shifts on SSCP analysis revealed normal wild-
type sequences.
The MEN1 gene encodes a 610-amino
acid protein which has no homology to pre-
viously known proteins. The frequent find-
ings of loss of heterozygosity (LOH) of 11q13
in MEN1-related tumors and their sporadic
counterparts, together with the demonstra-
tion of somatic mutations in the latter group,
imply that the gene is a tumor suppressor
gene (8), which has been considered as a
candidate for the genesis of adrenal and
thyroid neoplasms. There are several studies
using LOH technique indicating that 11q13
is involved in both of these neoplasms. With
regard to the adrenals, LOH on chromosome
11q13 has been observed in about 20% of
adrenal adenomas but the prevalence of LOH
increases up to 100% of the adrenal carcino-
mas investigated (9,10). Overall, LOH was
present in 23 of 44 (52%) cases examined by
different technical approaches (10). Con-
cerning thyroid tumors, 11q13 has been found
to be affected in 15 to 33% of the cases
investigated using microsatellite markers (11-
13). Also 11q13 was found to be more fre-
quently absent or inactivated in malignant
thyroid phenotypes such as follicular and
anaplastic carcinomas (11-13). In addition,
LOH has been demonstrated in many non-
MEN1-related tumors like breast cancer,
where it has been suggested to harbor a
tumor suppressor gene implicated in the tran-
sition from early preneoplastic lesions to
invasive breast cancer (14). Recently, the
MEN1 gene has been cloned from the 11q13
Table 1. Primers used to amplify the exon 2 sequence of the MEN1 gene. The sequence of the
primer, the localization and length of the corresponding fragment and the annealing tempera-
ture of each primer are described.
Primers Sequence Fragment Annealing
temperature
A Sense TTG CCT TGC AGG CCG CCG CC 2254®2456 = 202 bp 62oC
A Antisense TGG TAG GGA TGA CGC GGT TG
B Sense GGC TTC GTG GAG CAT TTT CT 2411®2612 = 201 bp 55oC
B Antisense CTC GAG GAT AGA GGG ACA GG
C Sense TTC ACC GCC CAG ATC CGA GG 2564®2759 = 195 bp 52oC
C Antisense TAA GAT TCC CAC CTA CTG GG
H Sense TTA GCG GAC CCT GGG AGG AG 2195®2421 = 226 bp 62oC
H Antisense TCC ACG AAG CCC AGC ACC AAG
J Sense CTG GCG GCC TCA CCT ACT TTC 2502®2653 = 151 bp 62oC
J Antisense GGA GAC CTT CTT CAC CAG CTC AC
Figure 1. Gel of single-stranded conformation polymorphism (SSCP) analysis representative
of our results for exon 2 in the multiple endocrine neoplasia type 1 (MEN1) gene screening
for mutations. PCR products were loaded from normal tissue from the contralateral lobe of
a thyroid follicular carcinoma (lane 1), from the thyroid follicular carcinoma of the same
patient loaded on lane 1 (lane 2), from a thyroid papillary carcinoma (lane 3), adrenocortical
carcinoma (lane 4), adrenocortical carcinoma (lane 5), adrenal adenoma (lane 6), breast
infiltrating ductal cancer (lane 7), and thyroid papillary carcinoma (lane 8).
1 2 3 4 5 6 7 8
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region and somatic mutations have been dem-
onstrated in MEN1 patients, who are charac-
terized by a predisposition to develop para-
thyroid, pituitary and pancreas tumors and
also adrenal cortex and thyroid lesions (1,
2,15).
In this context, we also screened a large
series of endocrine and nonendocrine tu-
mors for exon 2 of the MEN1 gene, where
most of the mutations in sporadic tumors
have been described (5-8). Our results sup-
port similar findings reported by Schulte et
al. (9,10) in adrenal lesions and by Nord et
al. (12) in thyroid tumors. Among our breast
tumors we also could not identify any muta-
tion of exon 2 of the MEN1 gene. We were
unable to find any literature reference to
MEN1 gene studies in breast tumors. Simi-
larly, the gene has also not been found to
participate in the tumorigenesis of other non-
endocrine tumors like lipomas and melano-
mas, although these tumors also do present
high rates of LOH on 11q13 (16,17). The
technique we used, SSCP, has a limited sen-
sitivity and may have not detected small
deletions involving the other exons of the
gene we did not screen. A screening method
for mutations that presents higher sensitivi-
ty, dideoxyfingerprinting, has detected many
somatic and germline mutations distributed
across the gene in familial MEN1 patients
(18). On the other hand, loss of function of
tumor suppressor genes usually requires large
deletions of chromosomal material. There-
fore, our results add to other similar findings
on thyroid and adrenal tumors, indicating
the possible presence of another different
tumor suppressor gene located in this chrom-
osomal area but outside the MEN1 linkage
interval (9,10,12). Interestingly, a previous
study of sporadic endocrine pancreatic tu-
mors has also implicated the involvement of
a second locus close to MEN1 (19). Another
possibility is the existence of a modifier
gene that may act in concert with the MEN1
gene altering the predisposition to tumori-
genesis. Indeed, there is clinical and experi-
mental evidence that one or more modifier
genes may act in conjunction with the APC
gene to alter predisposition to tumor forma-
tion at extracolonic sites such as the thyroid
gland in patients with familial adenomatous
polyposis (20).
In conclusion, by studying a large series
of tumors, we demonstrated that exon 2 of
the MEN1 gene is not involved in thyroid,
adrenal or breast tumorigenesis. Our results
and those reported by others suggest that a
tumor suppressor gene in 11q13 other than
MEN1 might be involved in the development
of these cancers.
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